Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Personal Dose: A New Direction and Profit Source?

By Drug Discovery Trends Editor | November 30, 2007

Industry Insider

A “personal dose” model could be a blockbuster alternative

Girish Malhotra

The business model of major pharma companies for recent times has been to develop and sell blockbuster drugs. With the expiration of about $100 billion in patents by 2011, major pharma companies have to look at other means to capture that revenue. This model is becoming uneconomical. In addition, generics pharma companies are also entering the ethical drug market. This is going to dilute the revenue and earnings of the big 10 pharma companies and add additional pressures to improve the business model.

Another avenue to capture revenue is to combine the existing drugs on the market so that their synergies can be used for cures. This hit-and-trial model’s success rate depends on identifying the drug combination values, business negotiation, and regulatory approval. We are seeing increasing use of this strategy. This drug combination model might extend the profits for a short time until the patents expire. Drug combination is an extension of the blockbuster model and can be considered a prelude to still another new model.

The “personal dose” model is based on genetics. Recent advances in genomics provide the necessary tools and will facilitate the drug development and commercialization for this business model. The personal dose model could be characterized as being in its test tube stage. Warfarin (Coumadin)1 is an example. Currently the proper dose has to be determined using genetic testing through repeated visits to a specialized clinic. This is expensive and a challenge for the physician and the patient—an aspect of the model that must be refined.

MORE ON BIOMARKERS

The Blockbuster Alternative
The blockbuster model has served Pharma well, but has limitations. An information-based medicine model uses biomarkers, adaptive clinical trials, and modeling and simulation to select compounds and subjects for testing.
Read the article.

ANOTHER POINT OF VIEW
The Biomarker Conundrum
Science is demonstrating that biomarkers can be used for diagnosis, drug discovery, dosing, and as clinical trial endpoints. However, regulatory, scientific, and commercial hurdles remain.
Read the Industry Insider feature.

For the personal dose model to be used widely, the following challenges have to met:

  1. Genetic testing has to be simple, quick, and foolproof so that the test can be performed in physician’s office or a similar facility.
  2. Personnel in the physician’s office must be trained to correctly read and interpret the test results.
  3. Genetic harmonization is needed so that the testing process is easy and simple.
  4. Drug regulatory agencies must develop and implement methods that allow and approve dose variation and changes to suit individual needs.
  5. Social and privacy advocates will have to see the benefits, chime in, and let go of some of their inhibitions.
  6. The results of genetic testing must be handled carefully as the information could be used to deny employment or insurance coverage if the testing to cure an existing condition showed potential mutation leading to development of a disease that could be labeled “pre-existing”.

Once the pharmaceutical companies, regulatory agencies, and others have overcome the above, personalized dose could become the norm and a high-volume business.

Even with wide use of personalized dose, however, the drug efficacy and safety would always be under considerable scrutiny. There could be ongoing debates among the social and privacy pundits. For success, collaboration would be needed between the pharmaceutical companies, test developers, regulatory agencies, and social gatekeepers. Work on simplification and cost reduction of DNA coding is being driven by five companies.2 In the end, the personal dose model could be highly profitable and valuable if the social and ethical hurdles can be overcome and the drug dispensing process is simplified.

This opportunity is also being considered by companies in India. Companies in developed countries must keep an eye on these developments.3

1. PERSONAL DOSE: In Milestone, FDA Pushes Genetic Tests Tied to Drug, Wall Street Journal, August 16, 2007.
2. DNA Decoding Maps Mainstream Future, Wall Street Journal, October 4, 2007.
3. Coming soon: Drugs to suit your genetic profile, The Economic Times, October 3, 2007.

About the Author
Girish Malhotra, president of EPCOT International (Pepper Pike, Ohio) has 40 years of experience in Pharmaceutical, Specialty, Custom and Fine chemicals, in manufacturing, process and technology development, and business development.

 


Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE